Page 8
www.us-
tech.com
May, 2019
Wacker Chemical Expands its Biotech Operations
Continued from page 1
by the group’s silicones division. The global production and serv-
Did you know?
Omron has been the trusted partner for inspection for over 30 years
Largest global supplier of 3D AOI systems
ice network operated by Wacker Biosolutions now comprises seven pro- duction sites and four technical cen- ters in Germany, Singapore, the U.S., and China. The integrated site in Burghausen, Germany, supplies fine chemicals and polyvinyl ac- etate solid resins, with other resins provided from the company’s facili- ty in Nanjing, China. The Ed- dyville site in Iowa, U.S., produces cyclodextrins and the León site in Spain makes L-cystine.
30 Years of Biotech The red brick walls in south-
east Amsterdam have been home to biotech facilities for 30 years. The recently acquired site’s history began in 1989 with the founding of EuroCetus B.V. by the US Cetus Cor- poration, targeting commercial pro- duction of the cancer drug ProLeukin II in Europe. Shortly after approval for the
active was obtained in 1992, the com- pany was taken over by Chiron Cor- poration and renamed Chiron B.V. After Novartis acquired Chiron Cor- poration in 2000, SynCo Bio Part- ners B.V. was spun off as an inde- pendent full-service contract manu- facturer. Wacker then took over 18 years later. Some 110 employees work at
the Amsterdam site today. The plant consists of two fermentation lines, a single-use equipment line, and a fill- and-finish facility for filling sterile solutions into vials. The site has pro- duction rooms that comply with the highest cleanroom classification — Class A. The Amsterdam site also has a
lyophilization facility, where active in- gredient solutions can be freeze-dried. This often improves their stability, i.e. their shelf life. Amsterdam’s three production lines have a combined fer- menter volume for pharmaceutical ac- tives of some 2,000 liters. The company’s biopharmaceuti-
The most advanced 3D CT AXI platform
cals business has seen strong per- formance. Since 2014, sales have risen by an average of 19 percent each year. Among the company’s core competencies are the production of therapeutic chemical actives, live bacteria and vaccines, including qual- ity control and quality assurance. The service portfolio also includes the development and validation of new production processes and the build-
up of cell lines and cell banks. Increased U.S. Footprint The company has also made re-
cent major investments in North America. In 2016, the company opened a $2.5 billion polysilicon pro-
With last year’s takeover of SynCo Bio Partners B.V., Wacker Biotech has doubled its capacity.
duction site in Charleston, Tennessee, which churns out around 20,000 met- ric tons of pure polysilicon per year. This polysilicon is then used in the production of silicon wafers and solar cells.
The Wacker Group’s U.S. head-
quarters are located in Adrian, Michi- gan. The 240-acre site has been pro- ducing elastomers, silicone fluids and silicone emulsions since 1969. The fa- cility offers a comprehensive range of services, including Wacker Academy, a program that shares the company’s extensive
collective knowledge
through tailored seminars. This year, the company expects
to further enhance capacity for liquid silicone rubber, high- and room-tem- perature-vulcanizing silicones and thermally conductive silicones at its production sites worldwide. Recently it was reported that Wacker was evaluating the option of building a plant for solid silicone rubber at its Charleston site. In the electronics industry, the
company’s silicones bond and seal, offering protection from dirt, mois- ture, radiation, and heat. This sili- cone is also used in electrical insula- tion, elastomers, fluids and gels for power transmission and distribution networks, wires, and cables. Wack- er’s silanes are key materials for the manufacturing of electronic devices. Their high purity and low concentra- tion of metal impurities make them excellent for many processes in semi- conductor production. Contact: Wacker Chemical
Corp., 3301 Sutton Road, Adrian, MI 49221 % 517-264-8500 Web:
www.wacker.com r
High and Low Current Organic Semiconductors
Continued from page 1
www2.omron.com/ustech
See at NEPCON China, Booth 1J45, SMTconnect, Hall 4A Booths 344 and 346, and EDS, Trinidad B
sistor design which combines the ability to drive high currents that is typical of classical transistors with the low-voltage operation required for use as artificial synapses,” says Weitz. With the successful assembly and characterization of vertical or- ganic field-effect transistors with ex- actly selectable dimensions and an ionic gating, this goal has now been achieved. Potential areas of application
for the new devices include OLEDs and sensors where low voltages, high on-state current densities or large
transconductances are required. Their possible use in so-called mem- ristive elements is of special interest. “Memristors can be thought of
as artificial neurons, as they can be used to model the behavior of neu- rons when processing electrical sig- nals,” explains Weitz. “By fine-tun- ing the geometry of a memristive de- vice, it could be applied in a variety of contexts, such as learning process- es in artificial synapses.” The re- searchers have already submitted a patent application for the device to enable them to develop the new tran- sistor architecture for industrial use. Web:
www.uni-muenchen.de r
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124
